Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 27, 2012

BD Acquires Sirigen Group

  • BD (Becton, Dickinson and Company) acquired Sirigen Group, a developer of polymer dyes that are used in flow cytometry and can be applied to other technologies.

    According to the company, Sirigen’s polymer technology is based on Nobel Prize-winning research in conductive plastics and creates the potential for the development of novel dyes that are four to ten times brighter than conventional dyes.

    “This new technology is a natural complement to our instrument platforms and reagent portfolio,” said Alberto Mas, president, BD Biosciences. “We believe that the acquisition will enable us to develop a continuous cadence of novel, unique dyes and antibody specificity releases over the next two years, significantly expanding our life science research reagent portfolio with high-impact products.”

    The financial terms of the acquisition were not disclosed.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »